Fosun Pharmaceutical Obtains Breakthrough Therapy Designation for Cancer Drug

MT Newswires Live

05/13

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.

The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.

Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.

Shares rose 2% in Shanghai during Tuesday's afternoon trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535791297"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535791297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535791297?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 14:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535791297","market":"nz","top_or_hot":-1,"title":"Fosun Pharmaceutical Obtains Breakthrough Therapy Designation for Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.</p><p>The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.</p><p>Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.</p><p>Shares rose 2% in Shanghai during Tuesday's afternoon trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharmaceutical Obtains Breakthrough Therapy Designation for Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharmaceutical Obtains Breakthrough Therapy Designation for Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-13 14:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.</p><p>The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.</p><p>Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.</p><p>Shares rose 2% in Shanghai during Tuesday's afternoon trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535791297","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535791297","pubTimestamp":1747119511,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical  obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.Shares rose 2% in Shanghai during Tuesday's afternoon trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0187":"一线龙头","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0096":"民营医院","BK1191":"制药","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股","BK1593":"医美概念股","00656":"复星国际","02196":"复星医药","BK0196":"行业龙头","BK0060":"抗癌"},"translate_title":"复星医药获癌症药物突破性疗法认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.Shares rose 2% in Shanghai during Tuesday's afternoon trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}